Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruiting

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma

NCT06576180
recruiting

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma

NCT06575322
recruitingphase_3

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

NCT05582265

Clinical Trials (3)

Showing 3 of 3 trials
NCT06576180

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06575322

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Recruiting
NCT05582265Phase 3

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3